Variable | Without liver metastasis 119 subjects | With liver metastasis 122 subjects | P Value |
---|---|---|---|
Portal hypertension* | 39/119 (33%) | 30/122 (24%) | 0.2 |
Sinusoidal portal hypertension* | 4/119 (3%) | 9/122 (7%) | 0.3 |
Peritoneal carcinomatosis (PC)* | 73/119 (61%) | 77/122 (63%) | 0.8 |
Chylous ascites | 8/119 (7%) | 6/122 (5%) | 0.6 |
SAAG < 1.1 and total protein < 2.5 | 7/119 (3.5%) | 15/122 (12%) | 0.1 |
SAAG < 1.1 and total protein < 2.5 with no evidence of PC on cytology and or imaging | 1/119 (0.84%) | 1/122 (0.82%) | 1 |
Portal hypertension without PC** | 16/119 (13%) | 7/122 (6%) | 0.04 |
Sinusoidal portal hypertension without PC** | 2/119 (2%) | 2/122 (2%) | 1 |
PC based on positive cytology and or imaging | 85/119 (71%) | 105/122 (86%) | 0.007 |
PC without evidence of PC on cytology or imaging± | 18/119 (15%) | 10/122 (8%) | 0.1 |
Mixed pattern (High SAAG and evidence of PC on cytology and or imaging) | 23/119 (19.3%) | 23/122 (18.8%) | 1 |
Primary malignancy location | |||
 Breast cancer | 12/119 (10%) | 29/122 (24%) | 0.006 |
 Gastric cancer | 24/119 (20%) | 9/122 (7%) | 0.005 |
 Lung cancer | 32/119 (27%) | 16/122 (13%) | 0.009 |
 Ovarian cancer | 15/119 (13%) | 5/122 (4%) | 0.02 |
 Pancreatic cancer | 14/119 (12%) | 26/122 (21%) | 0.06 |
 Renal cancer | 13/119 (11%) | 13/122 (11%) | 1 |
 Colon cancer | 9/119 (8%) | 24/122 (20%) | 0.008 |
Treatment regimen | Â | Â | Â |
 Diuretics# | 21/119 (18%) | 24/122 (20%) | 0.7 |
 Paracentesis# | 18/119 (15%) | 40/122 (33%) | 0.001 |
 Peritoneal drain# | 35/119 (29%) | 19/122 (16%) | 0.01 |
 Shunt# | 1/119 (1%) | 0/122 (0%) | 0.5 |
 Chemotherapy/immunotherapy | 44/119 (37%) | 39/122 (32%) | 0.4 |